Research Article| Volume 17, ISSUE 1, P17-22, July 1993

Download started.


Passage of the menopause is followed by haemostatic changes

      This paper is only available as a PDF. To read, Please Download here.


      The passage of the menopause has been reported to be followed by a steadily increasing risk of cardio-vascular disease (CVD). Changes in the concentrations of certain coagulation factors and fibrinolytic components are considered risk factors for CVD. We evaluated the differences in some of these variables between a premenopausal group (A) n = 28) and two postmenopausal groups, one of women less than 18 months past the menopause (B) n = 28), the other of women more than 18 months past the menopause (C) n = 21). The variables measured were serum oestradiol content, plasma antithrombin III (AT III) activity, protein C activity and the plasma concentrations of tissue type plasminogen activator (t-PA) antigen, plasminogen activator inhibitor (PAI-I) antigen, and fibrinogen. As compared with the premenopausal women (group A), group C showed significantly higher values for AT III and protein C activity and for t-PA and PAI-I antigen; and group B and C both showed significantly higher fibrinogen concentrations. This probably means that haemostatic balance was maintained in the postmenopausal women, although the increased concentrations of fibrinogen and PAI-1 might constitute risk factors for the development of cardiovascular disease.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Kannel W
        • Hjortlund MC
        • Mc Namara PM
        • Gordon T
        Menopause and risk of cardiovascular disease: The Framingham study.
        Ann Intern Med. 1976; 85: 447-452
        • Johansson BW
        • Kaij L
        • Kullander S
        • Lennér H-C
        • Svanberg L
        • Astedt B
        On some late effects of bilateral oophorectomy in the age range 15–30 years.
        Acta Obstet Gynecol Scand. 1975; 54: 449-461
        • Rosenberg L
        • Hennekens C
        • Rosner B
        • Belanger C
        • Rothman KJ
        • Speizer FE
        Early menopause and the risk of myocardial infarction.
        Am J Obstet Gynecol. 1981; 39: 47-51
        • Ross RK
        • Paganini-Hill A
        • Mach T
        • Arthur M
        • Henderssen BE
        Menopausal oestrogen therapy and protection from death from ischaemic heart disease.
        Lancet. 1981; : 858-860
        • Busch TI
        • Burett-Conner E
        • Cowan LD
        • et al.
        Cardiovascular mortality and noncontraceptive use of oestrogen in women.
        in: Results from Lipid Research Clinics, Program Follow-up Study. 2nd edn. Circulation. 75. 1987: 1102-1109
        • Basdevant A
        • de Lignieres B
        • Simon P
        • Blache D
        • Ponsin G
        • Goy-Grant B
        Hepatic lipase activity during oral and parenteral 17 B-oestradiol replacement therapy: high density lipoprotein increase may not be antiatherogenic.
        Fertil Steril. 1991; 55: 1112-1117
        • Aznar J
        • Estelles A
        • Tormo G
        • Sapena P
        • Tormo V
        • Blanch S
        • Espana F
        Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronory artery disease.
        Br Heart J. 1988; 59: 535-541
        • Huber K
        • Resch I
        • Stefenelli TH
        • et al.
        Plasminogen activator inhibitor-1 levels in patients with chronic angina pectoris with or without angiographic evidence of coronary sclerosis.
        Thromb Haemost. 1990; 63: 336-339
        • Hamilton PJ
        • Allardlyce M
        • Ogston D
        • et al.
        The effect of age upon the coagulation system.
        J Clin Pathol. 1974; 27: 980
        • Chakrabarti R
        • Bronzovic M
        • North WR
        • et al.
        Effects of age on fibrinolytic activity and factors V, VII and VIII.
        in: 2nd edn. Proc R Soc Med. 68. 1975: 267
        • Hamsten H
        • Wiman B
        • de Faire U
        • Blombick M
        Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.
        N Engl J Med. 1985; 313: 1557-1563
        • Jacobsson K
        Studies on fibrinogen.
        Scand J Clin Lab Invest. 1955; 14 (Suppl.): 7
        • Fagerholm MK
        • Abildgaard K
        • Bergsjö P
        • Jacobsen JH
        Oral contraceptives and low antithrombin-III concentration.
        Lancet. 1970; : 1175
        • Ballaeisen L
        • Bailey J
        • Epping P-H
        • Schulte H
        • van de Loo J
        Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population. I. Baseline data on the relation to age, gender, body weight, smoking, alcohol, pill using and menopause.
        Thromb Haemost. 1985; 54: 475-479
        • Kannel WB
        • Wolf PA
        • Castelli WP
        • D'Agostino RB
        Fibrinogen and risk of cardiovascular disease.
        in: The Framingham study. 2nd edn. J Am Med Assoc. 258. 1987: 1183-1186
        • Schneidau A
        • Harrison MJG
        • Hurst C
        • Wilkes HC
        • Meade TW
        Arterial disease risk factors and angiographic evidence of atheroma of the carotid artery.
        Stroke. 1989; 20: 1466-1471
        • Wilhelmsen L
        • Svärdsudd K
        • Korsan-Bengtssen K
        • Larsson B
        • Welin L
        • Tibblin G
        Fibrinogen as a risk for stroke and myocardial infarction.
        N Engl J Med. 1984; 311: 501-505